Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

Trial Profile

Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs Tesetaxel (Primary) ; Capecitabine
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CONTESSA
  • Sponsors Odonate Therapeutics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 Trial design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2018 According to an Odonate Therapeutics media release, data will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top